Content area
Full Text
Forest Laboratories took another step forward in rebuilding its antidepressant business with the FDA's approval of Fetzima for major depressive disorder (MDD) in adults. Fetzima, discovered by France's Pierre Fabre Laboratories, is a once-daily serotonin and norepinephrine reuptake inhibitor.
New York-based Forest ($FRX) has been seeking new remedies for depression amid generic competition to its antidepressant Lexapro , sales of which have been declining. Forest also sells the antidepressant Viibyrd , which it gained...